Roche’s cobas HIV-1/HIV-2 Qualitative Test Receives the US FDA’s Approval to Detect HIV Infection

 Roche’s cobas HIV-1/HIV-2 Qualitative Test Receives the US FDA’s Approval to Detect HIV Infection

Roche’s cobas HIV-1/HIV-2 Qualitative Test Receives the US FDA’s Approval to Detect HIV Infection

Shots:

  • The US FDA has approved cobas HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas 6800/8800 Systems in the US. The test combines the confirmatory HIV testing and HIV-1/HIV-2 differentiation into one single test to identify appropriate treatment options
  • The higher sensitivity of PCR technology is used in the cobas HIV-1/HIV-2 Qualitative Test that can reduce the time-to-detection period by 1 week or more. The test provides clinicians critical diagnostic data for personalized treatment of patients with HIV
  • cobas HIV-1/HIV-2 Qualitative test is an in vitro nucleic acid amplification test for the qualitative detection and differentiation of HIV-1 and HIV-2 RNA in human serum and plasma

Click here ­to­ read full press release/ article | Ref: Roche | Image: Webduniya

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post